Yttrium-90 Radioembolization for Hepatocellular Carcinoma: What We Know and What We Need to Know

Publisher： Karger

E-ISSN： 1423-0232|84|1|34-39

ISSN： 0030-2414

Source： Oncology, Vol.84, Iss.1, 2013-02, pp. : 34-39

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Outcomes in CKD: What We Know and What We Need to Know

By  

Nephron Clin Pract, Vol. 114, Iss. 2, 2009-11 ,pp. : c95-c103

Karger

Access to resources Recommend Favorite

Reply to: “Sorafenib or 90Y loaded resin microsphere radioembolization for locally‐advanced hepatocellular carcinoma, what should we trust?”

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 6, 2015-06 ,pp. : 1780-1781

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sorafenib‐ or 90Y‐loaded resin microsphere radioembolization for locally advanced hepatocellular carcinoma, what should we trust?

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 6, 2015-06 ,pp. : 1779-1780

John Wiley & Sons Inc

Access to resources Recommend Favorite

Unintentional Gun Injuries, Firearm Design, and Prevention: What We Know, What We Need to Know, and What Can Be Done

By Frattaroli Shannon   Webster Daniel W.  

Journal of Urban Health: Bulletin of the New York Academy of Medicine, Vol. 79, Iss. 1, 2002-03 ,pp. : 49-59

Springer Publishing Company

Access to resources Recommend Favorite

Cystatin C: What More Do We Need to Know?

By  

Nephron Clin Pract, Vol. 93, Iss. 4, 2004-11 ,pp. : c122-c123

Karger

Access to resources Recommend Favorite